OncoBeta - epidermal radioisotope therapy
Jane Wishaw is the Vice President of Marketing and Communication at OncoBeta Therapeutics Pty Ltd. and OncoBeta Intl. GmbH. Jane is also the Owner of journeysbyjane, where Jane specializes in strategic marketing, publicity, design, writing, and photography. With a background in various industries such as banking, telecommunications, and resort management, Jane brings a wealth of experience to their current role in promoting OncoBeta's non-invasive, topical, and pain-free skin cancer treatment.
This person is not in any offices
OncoBeta - epidermal radioisotope therapy
OncoBeta® GmbH located in Garching near Munich is a manufacturer and service provider of innovative medical solutions specialized in the development and commercialization of state-of-the-art therapies utilizing epidermal radioisotopes. We are very proud to be a pioneer and innovator in the epidermal radioisotope sector, presently offering a therapeutic application for physicians to treat non-melanoma skin cancer. Our current flag ship solution is the Rhenium-SCT® (Skin Cancer Therapy) a novel treatment option for basal cell carcinomas (BCCs) or squamous cell carcinomas (SCCs) based on the local irradiation of tumors with the beta-emitter Rhenium-188. Rhenium-188 is an optimal isotope for the treatment of superficial lesions such as non-melanoma skin cancers due to its practical penetration of 2-3mm in human tissue. Since the radioactive Rhenium does not come in direct contact with the patient, the Rhenium-SCT® is seen as a patient-personalised brachytherapy with minimal radiation exposition and adverse effects. The Rhenium-SCT is a CE certified method arising from over 10 years of experience and clinical studies (>700 patients, >1900 lesions). It provides non-melanoma skin cancer patients with a single-session, painless, highly-effective non- surgical treatment with excellent aesthetic results and complete remissions in up to 98,5% of all cases. We are also currently evaluating further exciting applications and treatment possibilities with rhenium-188.